LOXL2 and hepatocellular carcinoma: The first selective inhibitor for LOXL2, LOXL2-IN-1 hydrochloride [97], has recently been identified to act to suppress Snail, HIF-1α, and VEGF, which are promotion factors in HCC invasion and angiogenesis [49].